MarketPulse
N

$NBIX

5 articles found
2 positive
0 negative
3 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Nxera Pharma Posts Strong Q1 2026 as Spinoff Centessa Fetches $7.8B Lilly Deal

Nxera Pharma reported JPY 11.3B Q1 revenue driven by R&D milestones. Spinoff Centessa agreed to $7.8B acquisition by Eli Lilly.
ABBVLLYCNTANBIXrevenue growthdrug discovery
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Neurocrine Advances Nxera's Schizophrenia Drug into Phase 2 with First Patient Dosed

Neurocrine Biosciences doses first patient in Phase 2 trial of NBI-1117570 for schizophrenia, triggering $22.5M milestone payment to partner Nxera Pharma.
NBIXPhase 2 clinical trialdrug discovery
The Motley FoolThe Motley Fool··Eric Volkman

Neurocrine Snaps Up Soleno for $2.9B, Betting Big on Rare Disease Drug

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in all-cash deal, paying $53/share—a 34% premium driven by Soleno's FDA-approved Vykat XR for Prader-Willi Syndrome.
SLNONBIXacquisitionFDA approval
BenzingaBenzinga··Vandana Singh

Neurocrine Acquires Soleno for $2.9B to Dominate Rare Disease Market

Neurocrine acquires Soleno for $2.9B to gain Vykat XR, a rare disease blockbuster generating $190M in 2025 revenue.
SLNONBIXacquisitionFDA approval
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biohaven Stock Crashes 70%, but $6M Insider Bet Hints at Turnaround Play

Sarissa Capital deploys $5.79M in beaten-down biotech Biohaven despite 70% stock decline, betting on upcoming late-stage trial data and obesity candidate.
CYTKBHVNNBIXstock declineFDA rejection